Article Details
Retrieved on: 2025-08-22 14:20:09
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Its oral candidate required massive daily doses, driving high dropout rates. Entera Bio (Nasdaq: ENTX), with its N-Tab oral peptide platform, aims to ...
Article found on: markets.financialcontent.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here